Wuxi Biologics (Cayman) Inc. 2269

Forbes China recently released the 2026 Forbes China ESG 50 list. WuXi Biologics was named to the list for its outstanding performance in sustainable development, Green CRDMO solutions and ESG digital innovation, and was highlighted by Forbes China as one of the representative companies in ESG data governance.

Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.

WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2026 ("Reporting Period").

BioPharma APAC recently published its Top 26 - Companies Leading Sustainable Biopharma Practices in 2026, highlighting leading sustainability practices across pharmaceutical companies, biotechnology firms and CRDMOs in Europe, North America and Asia Pacific, with a focus on Science Based Targets initiative (SBTi) commitments, value-chain decarbonization, green manufacturing, and sustainable operations. The list brings together global pharmaceutical leaders – such as MSD (Merck & Co.), Eli Lilly,

WuXi Biologics (Cayman) (SEHK:2269) has been included in the FTSE4Good Index Series for the sixth consecutive year, highlighting the company’s ongoing ESG recognition and prompting investors to reassess how this may relate to the stock. See our latest analysis for WuXi Biologics (Cayman). The latest FTSE4Good recognition comes as WuXi Biologics (Cayman) trades at HK$38.74, with a 30 day share price return of 11.97% and a year to date share price return of 19.05%. The 1 year total shareholder...

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been included in the FTSE4Good Index Series in recognition of its outstanding sustainability performance, marking the sixth consecutive year the company has received this distinction. The inclusion further underscores WuXi Biologics' long-term leadership in Environmental, Social and Governance (ESG) and highlights the Company's ability to consistently cre

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Hebei has successfully passed the Pre-License Inspection (PLI) by the U.S. Food and Drug Administration (FDA), supporting commercial manufacturing for a potential blockbuster autoimmune therapy.

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has achieved MSCI's highest AAA ESG rating and been included in the MSCI 2026 Selection Indexes for the fourth consecutive year, underscoring global capital markets' recognition of the company's sustainability commitment and leadership in the biopharmaceutical industry.

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi — Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1) — together with its Drug Product Packaging Center (DPPC), have received GMP certification from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA). The certification positions WuXi Biologics to provide end‑to‑end commercial manufacturing services — c

Large building taking shape off Belmont Street.

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production campaign. The manufacturing process execution was completed with zero deviations, while critical process parameters remained stable and yields reached expected levels, demonstrating robust process performance and strong execution capabilities. As

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site won the "Overall Excellence in Life Sciences" award, the highest recognition at the 2026 Life Sciences Industry Awards. The company also was named the winner of the "Life Sciences Team of the Year" and won the "Outstanding Contribution Award." The Life Sciences Industry Awards are among Ireland's foremost industry recognition programs, celebratin

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational, the facility will be the Company's key DP facility designed to meet the latest and most stringent requirements for international markets, with expected output of approximately 100 million units of pre-filled syringes and vials per year.

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the CDP Supplier Engagement Assessment (SEA) A List for the second consecutive year. The recognition highlights the company's leadership in engaging suppliers on climate-related issues and reflects its strong performance in governance, target-setting, Scope 3 emissions disclosure, and value chain engagement. The company has also been recogni

WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that its drug substance facility (MFG23) located in Suzhou has received Good Manufacturing Practices (GMP) certification from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA). The facility is providing integrated manufacturing services for Instituto Butantan's dengue vaccine (Butantan-DV) production project.

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included in the 2026 Dow Jones Best‑in‑Class World Index (DJ BIC World) and the Dow Jones Best‑in‑Class Emerging Markets Index (DJ BIC Emerging Markets).

Event context and recent share performance WuXi Biologics (Cayman) (SEHK:2269) has drawn investor attention after a mixed stretch in its share price, with the stock down 1.9% over the past day and 8.1% over the past month. See our latest analysis for WuXi Biologics (Cayman). Measured over longer periods, the picture is more mixed, with the share price down over the past quarter but a 1 year total shareholder return of 41.39% contrasting with weaker 3 and 5 year total shareholder returns. If...